In the meta-analysis of randomized clinical trials, albumin use for resuscitation was found to be significantly associated with a reduction in 90-day mortality among septic shock patients, with an OR of 0.81 (95% CI: 0.67–0.97), and might slightly improve the outcome of severe sepsis patients when compared to crystalloid [23]. This evidence concerns the gene ALB and septic shock.